Xenetic Biosciences Inc is a biopharmaceutical company committed to providing innovative solutions in genetic research and drug development. With a focus on improving patient outcomes, Xenetic strives to deliver advanced therapies for a wide range of diseases. The company believes in fostering a culture of collaboration and scientific excellence, working closely with leading experts and leveraging cutting-edge technologies. Xenetic's corporate philosophy emphasizes ethical practices, transparency, and a dedication to creating value for shareholders, employees, and the global healthcare community. By harnessing genetic engineering and biotechnology, Xenetic Biosciences Inc aims to revolutionize medical treatments and shape the future of personalized medicine.

Xenetic Biosciences Inc is primarily present in the United States.

Xenetic Biosciences Inc has achieved several significant milestones in its history. One of the notable achievements of the company was the successful completion of a Phase 2 clinical trial for its lead product candidate, XBIO-101. This drug is being developed for the treatment of progesterone receptor negative (PR-) breast cancer. Another notable milestone for Xenetic Biosciences Inc was the initiation of a Phase 1 study for its proprietary PolyXen platform technology. This technology offers a potential solution for improving drug delivery and enhancing the therapeutic benefit of existing treatments. Overall, Xenetic Biosciences Inc has made substantial progress in its drug development programs, positioning itself as an emerging leader in the biopharmaceutical industry.

Xenetic Biosciences Inc is a biopharmaceutical company specializing in the discovery and development of innovative therapies for rare diseases and oncology. Founded in 2011, Xenetic Biosciences has rapidly gained recognition for its cutting-edge technologies and advancements in biotherapeutics. With a focus on employing its proprietary PolyXen and OncoHist platforms, the company strives to improve the efficacy and safety profiles of existing drugs while also integrating next-generation biotherapeutic candidates into its pipeline. By leveraging its expertise in genetic engineering and protein modification, Xenetic Biosciences Inc aims to transform patient care and address unmet medical needs. This forward-thinking approach positions the company as an industry leader in the field of biotechnology.

The main competitors of Xenetic Biosciences Inc in the market include companies such as BioMarin Pharmaceutical Inc, bluebird bio, Inc, Sangamo Therapeutics, Inc, and Spark Therapeutics, Inc. These companies operate in the biotechnology and pharmaceutical industry and compete with Xenetic Biosciences in developing novel therapies and treatments. In terms of product portfolio and market presence, these competitors pose significant challenges for Xenetic Biosciences as it strives to establish its unique position and gain market share. However, Xenetic Biosciences continues to focus on innovative research and strategic collaborations to differentiate itself from its competitors and provide valuable solutions in the industry.

Xenetic Biosciences Inc primarily operates in the biotechnology industry.

The business model of Xenetic Biosciences Inc revolves around developing and commercializing innovative biopharmaceutical products. The company employs its proprietary technology platform, PolyXen™, to create novel drug candidates with improved therapeutic profiles. Xenetic Biosciences Inc focuses on employing this platform to advance a range of therapeutic products in areas like oncology, immunology, and neurology. By leveraging their expertise in protein engineering, the company aims to generate value for both patients and shareholders through the development and commercialization of differentiated drugs.

مُعامل القيمة السوقية إلى الأرباح لـ Xenetic Biosciences هو ؜-٣٫٨٤.

مُعامِل القيمة إلى المبيعات Xenetic Biosciences هو ٢٫٧١.

نقاط جودة AlleAktien لـ Xenetic Biosciences هي 3/10.

المتوقعة Xenetic Biosciences الإيرادات هي ٢٫٢٤ مليون. USD.

صافي الربح المتوقعة Xenetic Biosciences هو ؜-١٫٥٩ مليون. USD.

Xenetic Biosciences Inc is a company that focuses on the development of biopharmaceuticals and therapies for various diseases and conditions. The business model of Xenetic Biosciences includes research, development, licensing, and marketing of products in various areas such as oncology, neurology, infectious diseases, and blood diseases.

يوزع Xenetic Biosciences أرباحًا قدرها 0 USD من خلال عمليات توزيع موزعة على مدار السنة.

لا يمكن حساب الأرباح السنوية لـ Xenetic Biosciences في الوقت الحالي أو أن الشركة لا توزع أرباحًا.

الرمز الدولي للأوراق المالية الخاص بـXenetic Biosciences هو US9840155033.

رمز WKN لـ Xenetic Biosciences هو A2PMYU.

الرمز المُختصر لـ Xenetic Biosciences هو XBIO.

خلال آخر 12 شهراً، دفعت Xenetic Biosciences توزيعات أرباح بقيمة . وهذا يعادل عائد توزيعات أرباح يقارب . ومن المتوقع أن تدفع Xenetic Biosciences خلال الـ12 شهراً القادمة توزيعات أرباح تقدر بـ0 USD.

نسبة توزيعات الأرباح الحالية لـ Xenetic Biosciences هي .

Xenetic Biosciences يدفع توزيعات أرباح ربع سنوية. يتم توزيعها في الأشهر .

Xenetic Biosciences دفعت توزيعات الأرباح كل عام خلال الـ0 سنوات الماضية.

يُتوقع خلال الـ12 شهرًا القادمة توزيع أرباح بقيمة 0 USD. وهذا يعادل عائد توزيعات أرباح قدره 0 %.

Xenetic Biosciences يُصنف ضمن قطاع 'الصحة'.

لكي تستلم آخر توزيعات أرباح بقيمة 0 USD من Xenetic Biosciences المُعلن عنها في ١٧‏/٩‏/٢٠٢٤، كان يجب أن تمتلك السهم في محفظتك قبل تاريخ الاستحقاق السابق في ١٧‏/٩‏/٢٠٢٤.

تم توزيع آخر دفعة من الأرباح بتاريخ ١٧‏/٩‏/٢٠٢٤.

في العام 2023، وزعت Xenetic Biosciences 0 USD كأرباح أسهم.

يتم توزيع أرباح Xenetic Biosciences بالعملة USD.